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Abstract
Background: Insulin degrading enzyme (IDE) is implicated in the regulation of amyloid β (Aβ)
steady-state levels in the brain, and its deficient expression and/or activity may be a risk factor in
sporadic Alzheimer's disease (AD). Although IDE sub-cellular localization has been well studied, the
compartments relevant to Aβ degradation remain to be determined.
Results: Our results of live immunofluorescence, immuno gold electron-microscopy and gradient
fractionation concurred to the demonstration that endogenous IDE from brain tissues and cell
cultures is, in addition to its other localizations, a detergent-resistant membrane (DRM)-associated
metallopeptidase. Our pulse chase experiments were in accordance with the existence of two
pools of IDE: the cytosolic one with a longer half-life and the membrane-IDE with a faster turn-
over. DRMs-associated IDE co-localized with Aβ and its distribution (DRMs vs. non-DRMs) and
activity was sensitive to manipulation of lipid composition in vitro and in vivo. When IDE was mis-
located from DRMs by treating cells with methyl-β-cyclodextrin (MβCD), endogenous Aβ
accumulated in the extracellular space and exogenous Aβ proteolysis was impaired. We detected
a reduced amount of IDE in DRMs of membranes isolated from mice brain with endogenous
reduced levels of cholesterol (Chol) due to targeted deletion of one seladin-1 allele. We confirmed
that a moderate shift of IDE from DRMs induced a substantial decrement on IDE-mediated insulin
and Aβ degradation in vitro.
Conclusion: Our results support the notion that optimal substrate degradation by IDE may
require its association with organized-DRMs. Alternatively, DRMs but not other plasma membrane
regions, may act as platforms where Aβ accumulates, due to its hydrophobic properties, reaching
local concentration close to its Km for IDE facilitating its clearance. Structural integrity of DRMs
may also be required to tightly retain insulin receptor and IDE for insulin proteolysis. The concept
that mis-location of Aβ degrading proteases away from DRMs may impair the physiological turn-
over of Aβ in vivo deserves further investigation in light of therapeutic strategies based on
enhancing Aβ proteolysis in which DRM protease-targeting may need to be taken into account.
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Background
Insulin degrading enzyme (IDE) is a thiol zinc-metal-
lopeptidase involved in the hydrolysis of several peptides
including insulin and amyloid β (Aβ) [1,2] and impli-
cated in regulating cellular growth and differentiation [3].
Subcellularly, IDE is primarily found in cytosol [4], perox-
isomes [5] and plasma membrane (PM) [6]. In addition,
a secreted form of IDE has been found in conditioned
media of cell lines and primary neuronal cultures [7]. The
primary structure of IDE does not indicate the presence of
a signal peptide for entering the secretory pathway or any
predicted membrane-associated domains that could
explain its association with membranes and its secretion.
Aβ is the major component of amyloid plaques, a patho-
logical hallmark of Alzheimer's disease (AD). In addition
to IDE, Aβ can be degraded by several proteases, including
neprilysin (NEP), endothelin converting enzyme-1 (ECE-
1), plasmin, and matrix metalloproteinases (MMPs) [8].
There is compelling evidence supporting the physiologi-
cal role of IDE in the degradation and homeostasis of Aβ
and insulin. Recent studies in animal models support a
pivotal role of IDE in Aβ catabolism. Firstly, diabetes-
associated mutations in rat IDE impair Aβ degradation
[9]. Secondly, cerebral Aβ levels are elevated and hyperin-
sulinemia and glucose intolerance are seen in IDE knock-
out mice [10]. Finally, overexpression of IDE in transgenic
AD mouse models decreases Aβ levels and retards the for-
mation of amyloid plaques [11].
Several reports indicate that insulin degradation by IDE
requires binding to its receptor, reported to reside in
DRMs [12] in all the tissues and cell types studied [13-15].
Noteworthy, the mechanisms by which IDE accesses each
substrate for degradation are not clear and neither the
functional significance nor a systematic study of the asso-
ciation of endogenous IDE with membranes in cultured
cells or brain tissue have been explored so far. Therefore,
here we asked whether there is a pool of proteolytically
active IDE associated with plasma membrane DRMs and
its participation in Aβ and insulin degradation.
Methods
Antibodies and chemicals
Anti-IDE polyclonal (BC2) and monoclonal (1C1 and
3A2) antibodies were generated and characterized in our
laboratory as described [16,17]. All of them are reactive
against human, rat and mouse IDE. BC2 recognized linear
epitopes within amino acids 97–273 of rat IDE, while
both monoclonal antibodies (isotype IgG1a) are reactive
for different epitopes within residues 262–530. Rabbit
polyclonal S40 antiserum was provided by Dr. Mikio
Shoji (Okayama University, Okayama, Japan) it is specific
for Aβ-40 and does not recognize APP. Rabbit anti-APP C-
terminal (AB5352) was from Chemicon. Purified mono-
clonal antibody against flotillin-1 was purchased from BD
Transduction Laboratories. Mouse monoclonal antibody
anti-tubulin and polyclonal antibody anti-actin were
from Sigma. When indicated, experiments were per-
formed in the presence of a protease inhibitor cocktail
defined as: 10 mM PMSF, 20 μM leupeptin, 20 μM apro-
tinin, 50 μM thiorphan and 50 μM phosphoramidon with
or without metalloproteinase inhibitors (5 mM EDTA and
1 mM 1,10 phenanthroline).
Cell cultures
N2a cells (mouse neuroblastoma) from the American
Type Culture Collection (ATCC) # CCL-131 were cultured
in 50% Dulbecco's modified Eagle's medium (DMEM)
and 50% Opti-MEM (Invitrogen) supplemented with 5%
fetal bovine serum (FBS). N2aSW cells (N2a cells stably
expressing human APP Swedish mutation [18] and
N2aEGFP (N2a cells stably expressing the vector pEGFP),
were cultured in the above N2a culture media supple-
mented with 400 μg/ml of G418 (Sigma). Primary cul-
tures of hippocampal neurons were prepared from Wistar
rat embryos of 17–18 days. Briefly, cells from hippocam-
pus were dispersed with trypsin (0.24 mg/ml, GIBCO) fol-
lowed by addition of Advanced-DMEM (GIBCO)
supplemented with 5% FBS. Cells were washed twice with
Hanks Balanced Salt solution (HBSS, GIBCO) and plated
in Neurobasal medium (NB, GIBCO) containing 2% B27
supplement (GIBCO) and 0.5% glutamine (GIBCO).
Tissues
Frozen postmortem brain samples from a previously char-
acterized FAD patient [19] were obtained from the
Department of Pathology, Hospital Santojanni, under the
approval of the Institutional Ethics Committee. Adult
intact female Wistar rats (200–250 g) were maintained on
a 12 hour light/dark cycle, fed with standard diet, and
housed according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Ani-
mals were killed by decapitation at random points of the
estrous cycle and the brain processed as described below.
Heterozygous breeding pair mice with targeted deletion of
one seladin-1 allele were kindly provided by Dr. E. Fein-
stein (Quark Pharmaceuticals Inc.). These mice were gen-
erated for Quark Pharmaceuticals by Lexicon Corp. under
the service agreement. Seladin-1 deficient mice were bred
and genotyped as previously described [20]. All animal
experiments and husbandry were performed in compli-
ance with national guidelines. The brains of Seladin-1 het-
erozygous (+/-) and wild type (+/+) mice were analyzed at
3 weeks of age.
Immunoelectron Microscopy of endogenous IDE
Confluent cultures were washed and fixed with 2% p-for-
maldehyde (PFA)/0.5% glutaraldehyde. Cells were recov-Molecular Neurodegeneration 2008, 3:22 http://www.molecularneurodegeneration.com/content/3/1/22
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ered with a cell-scraper and extensively washed with PBS.
Pellets were dehydrated in ethanol and propylene oxide,
embedded in LR White (Polysciences, Inc. Warrington, PA
USA) and polymerized. After thin sectioning (750–900 )
samples were collected on carbon-formvar-coated nickel
grids and processed using the immunogold technique.
Briefly, grids were sequentially blocked with 0.02 M gly-
cine and 1% bovine serum albumin (BSA)/5% normal
goat serum in PBS and labeled with primary antibodies
for 45 minutes at room temperature. After washing grids
were incubated with anti-mouse and/or anti-rabbit IgG
conjugated to colloidal gold particles of 15 nm and 6 nm,
respectively (Electron Microscopy Sciences, Hatfield, PA
USA). Control labeling was performed with a non-related
mouse IgG instead of the primary antibody. Sections were
post-fixed with 2% PFA/0.5% glutaraldehyde, washed,
stained with 2% uranyl acetate and observed in a JEOL
1200 EX electron microscope (Akishima, Tokyo, Japan).
DRMs and IDE live staining immunofluorescence
DRMs were stained on living N2a cells and primary hip-
pocampal neurons with Vybrant Lipid Raft Labeling Kit
(Molecular Probes-Invitrogen) following the manufac-
turer's instructions. Alexa fluor 594 conjugated to cholera
toxin sub-unit B (CT-B) was used to label gangliosides on
the PM followed by incubation with anti-CT-B polyclonal
antibody in order to "patch" DRMs. For staining endog-
enous IDE associated to PM, cells were incubated with 0.5
mg/ml of 1C1 and 3A2 anti-IDE monoclonal antibodies
for 1 hour at 4°C, extensively washed, and probed with
anti-mouse Alexa 488 (green) or anti-mouse Cy3 (red)
antibody for 1 hour at 4°C. Cells were then fixed with 4%
PFA and mount on fluorescent mounting medium (Dako-
Cytomation). Double-labeling analysis was performed by
laser scanning confocal microscopy imaging of slides on a
LSM5 Pascal Zeiss (Oberkochen) microscope using a
three-frame filter and a Zeiss LSM5 image examiner.
Assessment of co-localization of CT-B and IDE immuno-
reactivity was performed using the Image-Pro Plus soft-
ware (Media Cybernetics)
Subcellular fractionation
Cells were re-suspended in hypotonic buffer (10 mM KCl;
10 mM Tris-HCl; 1.5 mM MgCl2; 1 mM PMSF; pH 7.5)
passed through a 21G-gauge needle several times and cen-
trifuged at 4,000 × g for 5 minutes to pellet nuclei and
nuclei-associated structures, including Golgi and endo-
plasmic reticulum membranes. The supernatant was cen-
trifuged at 100,000 × g for 60 minutes in a 50 Ti rotor
(Beckman) at 4°C to obtain a pellet containing the PM-
enriched fraction as previously described [21]. Pellets
were exhaustively washed in 0.5 M Na2CO3, pH 11 and
centrifuged at 100,000 × g at 4°C for 1 hour. Both, PM-
enriched and cytosolic fractions were solubilized in NP-
40 lysis buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl;
0.5% NP-40) and stored at -80°C for further analysis.
Determination of cytosolic and membrane-associated IDE 
turnover
Cells were labeled in methionine-depleted medium (Inv-
itrogen) containing [35S]methionine (250 μCi/mL, GE
Biosciences). For pulse-chase experiments, after labeling
for 30 minutes cells were rinsed in PBS and incubated in
culture medium for the chase after: 48, 72 and 96 hours
for cytosolic IDE and 0.5; 1; 3; 6, 7.5; 11; 24 and 48 hours
for membrane associated IDE, respectively. After each
time-point, conditioned medium was recovered and cells
were rinsed in PBS, scraped and processed as described
above for sub-cellular fractionation except that PM-
enriched pellets were resuspended in PBS/0.5% Triton X-
100. Immunoprecipitations of IDE from cytosol and PM-
enriched fraction were performed by incubation with 30
μL of Protein G-Sepharose (GE Bioscience) and 1C1/3A2
(specific anti-IDE monoclonal antibodies). Pellets were
collected with a brief centrifugation, washed in 50 mM
Tris-HCl pH 7.5; 120 mM NaCl; 1% NP-40; 0.1% SDS and
analyzed by Tris- N-[2-hydroxy-1,1-bis (hydroxyme-
thyl)ethyl-]glycine (Tricine) polyacrylamide gel electro-
phoresis (SDS-PAGE) on a 7.5% gel, and subjected to
fluorography. The amount of radiolabeled IDE was esti-
mated with a Storm 840 PhosphorImager (GE Bio-
science). Each value of remaining radiolabeled IDE was
referred to the maximum value obtained during the chase.
The first-order decay constant (k) was calculated from one
phase exponential decay curves using the form y = e(-kt)
generated with the program GraphPad Prism 4. The half-
life of IDE was determined according to the formula t1/2
= 0.693/k.
Manipulation of lipid composition from PM-enriched 
fractions
Cells grown to confluence were washed once with PBS
and incubated with 5 mM methyl-β-cyclodextrin (MβCD)
(Sigma) in serum-free medium for 30 minutes at 37°C.
Chol replenishment of MβCD-treated cells was performed
by incubation with 1 mM water soluble Chol (Sigma) for
30 minutes at 37°C. The total lipid extracts were analyzed
by thin-layer chromatography (TLC) followed by chemi-
cal detection [22]. Identification of lipids separated by
TLC was accomplished by co-migration with standard lip-
ids. The relative amounts of each lipid were determined
by densitometry using the computer software Gel-Pro
Analyzer 3.1 (Media Cybernetics). Cholesterol level in
total cellular membrane was measure using a standar pro-
tocol previously described [23].
Quantification of extracellular endogenous A
N2aSW cells were treated or not with 5 mM MβCD in the
presence of a protease inhibitors cocktail and superna-Molecular Neurodegeneration 2008, 3:22 http://www.molecularneurodegeneration.com/content/3/1/22
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tants were collected after 12 and 24 hours. To assess if APP
processing was affected by MβCD treatment, endogenous
levels of APP C-terminal fragments were determined in
the cellular pellets by western blot as described below.
Aβ40 levels were quantified in the supernatants using a
commercially available ELISA kit (Covance Research
Products) following the manufacturer's instructions.
Cell surface degradation assay of extracellular A
Synthetic Aβ 1–40 was obtained from Bachem (Torrance)
and iodinated by the Chloramine-T method as described
[24]. For cell surface degradation assay, 30,000 cpm of
[125I]-Aβ40 (specific activity 15 μCi/μg) were added per
milliliter of medium to 90% confluent control and
MβCD-treated cells plated in 100 mm dishes and incu-
bated at 37°C for 15 minutes in the presence of protease
inhibitors as described above. Supernatants were removed
and treated with 15% trichloroacetic acid to precipitate
undegraded [125I]-Aβ40. The precipitated samples were
centrifuged, and the amount of cpm in the pellet (intact
peptide) was counted. Degradation was expressed as per-
centage compared to control referred as [125I]-Aβ40 incu-
bated in cell culture medium free of cells.
Isolation of DRMs and DSMs fractions from N2a cells, rat 
and human brain
Nearly confluent N2a cells grown in 100 mm dishes were
washed in PBS/9% sucrose/protease inhibitor cocktail.
Cellular homogenates were obtained after 10 strokes in a
dounce homogenizer and 10 passages though a 22 G
gauge needle syringe on ice. Samples were centrifuged for
10 minutes at 4°C and 700 × g and the supernatants fur-
ther centrifuged at 100,000 × g for 1 hour at 4°C to isolate
the membrane fraction. The final pellet was resuspended
in MES buffer saline (MBS) containing 1% Triton X-100,
passed through a 27 G × 1/2 -gauge needle 10 times and
incubated 30 minutes at 4°C. For sucrose density gradient
centrifugation, membrane lysates were adjusted to 60%
(w/v) final concentration of sucrose (final volume 2 ml)
and overlaid with 5 ml 35% and 5 ml 5% (w/v) sucrose in
MBS containing 0.5% Triton X-100. Samples were centri-
fuged in a SW 41-Ti rotor (Beckman) at 100,000 × g at
4°C for 20 hours. Rat and human brain tissues were proc-
essed as described [25]. Briefly, membranes were isolated
after sonication in MBS/protease inhibitor cocktail and
centrifugation at 100,000 × g at 4°C for 90 minutes. The
final pellet was resuspended in MBS containing 2% Triton
X-100 and incubated for 2 hours at 4°C. The lysate was
then loaded onto a sucrose gradient and processed as
described above for cells. Fractions were collected from
the top of each tube. For gradient characterization, protein
level was measured using a bicinchoninic acid assay
(Pierce). In each fraction, the density was calculated by the
refractive index and the alkaline phosphatase activity by
the generation of p-nitrophenol from nitrophenylphos-
phate monitored at 405 nm. DRMs (fractions 3 and 4)
were defined by 3 criteria: low-density, positive alkaline
phosphatase activity and the presence of flotillin-1 immu-
noreactivity. By contrast, DSMs corresponded to high den-
sity fractions (8 and 9) lacking alkaline phosphatase
activity and flotillin-1 immunoreactivity.
Quantification of endogenous A  in DRMs and DSMs from 
human brain
DRM and DSM fractions were mixed with 150 mM
sodium citrate (pH 7.0) at a 8:1 (vol:vol) ratio and centri-
fuged at 100,000 × g for 1 hour in a SW-40 Ti rotor (Beck-
man) at 4°C to pellet membranes and exchange the
buffer. The supernatant was discarded and the pellet was
sonicated in reaction buffer containing 150 mM sodium
citrate, pH 7.0/2% Brij-35, and complete protein inhibitor
PI (Sigma). Aβ42 levels were determined using a commer-
cially available ELISA kit (Covance Research Products) fol-
lowing the manufacturer's instructions.
Immunoprecipitation-based IDE activity assay
IDE was immunoprecipitated from DRMs and DSMs frac-
tions with 1C1 and 3A2 (anti-IDE monoclonal antibod-
ies). Monoclonal anti-actin was used as a negative control.
Immunocomplexes were isolated with protein G-Sepha-
rose (GE Biosciences) and then washed with ice-cold
buffer containing the protease inhibitor cocktail. Beads
were then incubated for 4 hours in 50 μl degradation
buffer (0.1 M phosphate, pH 7) containing 65,000 cpm of
[125I]-insulin (specific activity, 300 μCi/μg; kindly pro-
vided by Edgardo Poskus, University of Buenos Aires) or
[125I]-Aβ (specific activity, 20 μCi/μg) as described [16], in
the presence of the protease inhibitor cocktail with or
without metalloproteinase inhibitors, respectively. After
incubation, beads were centrifuged at 1,500 × g for 5 min-
utes and 20 μl of the supernatant were removed, mixed
with an equal volume of 8% SDS Laemmli sample buffer,
boiled, and resolved by 15% Tris-Tricine SDS-PAGE under
non-reducing conditions. The amount of intact remaining
[125I]-insulin or [125I]-Aβ, as compared to the undegraded
radiolabeled peptide in the negative control sample, was
estimated with a Storm 840 PhosphorImager (GE Bio-
science) and values expressed as percentage of intact pep-
tide.
Western Blotting
Proteins were resolved using 10% Tris-Tricine gels trans-
ferred to polyvinylidenedifluoride (PVDF) membranes
(GE Bioscience) and incubated with primary antibodies
(BC2, anti-tubulin, anti-flotillin-1 or anti-C-terminal APP,
respectively). Immunoreactivity was detected with anti-
rabbit or anti-mouse horseradish peroxidase-labeled IgG
(Dako) and enhanced chemiluminescence ECL Plus (GE
Bioscience). Immunoblots were scanned with Storm 840Molecular Neurodegeneration 2008, 3:22 http://www.molecularneurodegeneration.com/content/3/1/22
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and analyzed with ImageQuant 5.1 software (GE Bio-
science).
Statistical Analysis
All values are presented as means ± SE. ANOVA was used
to determine differences among groups. Where a signifi-
cant difference was indicated, the Tukey test was used to
determine significant differences between groups. p <
0.05 was considered to be statistically significant.
Results
IDE resides in DRMs of the plasma membrane
Immunocytochemistry without fixation and permeabili-
zation using specific and well-characterized anti-IDE
monoclonal antibodies (1C1 and 3A2) [17] in living N2a
cells wild type (N2aWT) or stably expressing EGFP
(N2aEGFP) showed a strong punctuated fluorescence
restricted to the cell surface consistent with a PM-associ-
ated protein (Fig. 1A) as previously reported using cell sur-
face biotinylation [26]. No reactivity was detected when
purified IgG from normal mouse serum was used (not
shown). Moreover, we confirmed this observation by
immunoelectron microscopy on anti-IDE-stained cryosec-
tions of N2aSW cells (Fig. 1B1). A higher magnification of
a portion (framed) of Fig. 1B1 showed a cluster of colloi-
dal gold particles of homogenous size (arrows) corre-
sponding to IDE (Fig. 1B2). These results are consistent
with the notion that IDE is located facing the outer side of
the PM. Pulse-chase experiments of metabollicaly labeled
IDE showed that cytosolic IDE peaked at time zero of
chase and decreased in 96 hours while membrane-associ-
ated IDE peaked after 6 hours of chase and decayed mark-
edly in 24 hours (Fig. 1C). A marked difference was
observed in the decay-rate with a half-life of 33 hours and
4 hours for cytosolic and membrane-associated IDE,
respectively. Together our results indicate that endog-
enous membrane-IDE follows a definite targeting and
clearance pathway that rules-out a contamination with
cytosolic IDE in our membrane preparations. To further
characterize PM-associated IDE we co-immunostained
PM-IDE and DRMs in living N2aWT cells (Fig. 2A panels
1–3) and in hippocampal primary neurons (Fig. 2A pan-
els 4–6). The pattern of reactivity showed individual red
(CT-B) and green (IDE) spots distributed in the cell sur-
face compatible with "patches" in the PM. We observed
that IDE partially co-localized with CT-B-labeled DRMs
(arrows) in both cell types. We determined that 14.7 ±
0.7% of PM-associated IDE co-localized with DRMs con-
taining GM1 in N2aWT cells. To confirm that IDE resides
in DRMs, we performed immunogold electron micros-
copy (IEM) on N2a cells using specific antibodies anti-
IDE and anti-flotillin-1, a widely used marker of DRMs. A
representative image is shown in Fig. 2B1. Higher magni-
fication of the framed portion selected in Fig. 2B1 (Fig.
2B2) clearly indicated the presence of colloidal gold parti-
cles of different sizes corresponding to IDE (15 nm, white
arrows) and flotillin (6 nm, black arrows). The co-locali-
zation of both antigens further indicates the presence of
IDE in DRMs and it is consistent in with the "patch" stain-
ing observed by immunofluoresence.
Endogenous IDE fractionates with DRMs isolated from 
human brain and N2a cells
We next used a biochemical approach to characterize the
association of IDE with DRMs. DRMs are sub-cellular
compartments that although do not correspond to lipid
rafts as they exist in vivo, their biochemical separation are
the only approach for assessing protein interactions with
lipid rafts [27,28]. N2a cell membranes were isolated,
treated with detergent at 4°C and subjected to sucrose gra-
dient centrifugation. All fractions from the sucrose density
gradient were analyzed by total protein distribution,
Plasma membrane and cytosolic IDE have different turn-over Figure 1
Plasma membrane and cytosolic IDE have different 
turn-over. A-Immunofluorescence of PM-associated endog-
enous IDE in living N2a wild type (N2WT) (panel 1) and 
Na2WT-EGFP (panel 2) cells using 1C1 monoclonal antibody 
and Alexa 488 (green) or Cy3 (red) anti-mouse IgG, respec-
tively. Expression of EGFP was visualized based on the EGFP 
fluorescence (green) and labeled the cytosolic compartment. 
Scale bars: 5 μm. B-Immunogold electron microscopy on 
cryosections of N2aSW cells showed a cluster of IDE mole-
cules at the PM (panel 1) which were more evident at higher 
magnification of the framed region (panel 2). Scale bar, 50 
nm. C- Representative phosphorimaging of the remaining 
IDE during the chase period in cytosol (upper panel) and PM 
(lower panel). N2aWT cells were pulse-labeled with [35S]-
methionine for 30 minutes and chased for the indicated times 
(0 to 96 hours). Cytosolic and PM fractions were immuno-
precipitated as described in Material and Methods. The inten-
sity of the bands was quantified and the maximal value was 
obtained at time cero and after 6 hours of chase for cytosolic 
and PM-associated IDE pools, respectively.
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refractive index and GPI-alkaline phosphatase activity
(Fig. 3A). In agreement with a previous report [25], most
of the alkaline phosphatase activity was located at the 5–
30% sucrose interface, representing the DRMs (fraction 3
and 4) while detergent-soluble membranes (DSMs) were
limited to fractions 8–9. Interestingly, as shown in Fig. 3B
IDE immunoreactivity was detected in DRM fraction
together with flotillin-1 which is over-represented in
DRMs as compared to DSM indicating that the biochemi-
cal fractionation of brain DRMs was properly performed.
To further investigate the co-residence of IDE with Aβ in
DRMs we isolated DRMs and DSMs from the cerebral cor-
tex of a familial AD case (carrying the PS1 mutation
M146L), known to present extensive Aβ accumulation
[19]. The presence of Aβ42 in DRM and DSM was corrob-
orated by sandwich ELISA assay (Fig. 3C). Substantial
peptide concentration was detected in DRM as compared
to DSM in agreement with previous reports [29]. Taking
into account the technical impossibility to perform a tri-
ple-immuno gold electron microscopy to detect IDE, Aβ
and flotillin we performed IEM on N2aSW cells to localize
IDE and Aβ (Fig. 3D1). A higher magnification of the por-
tion framed in Fig. 3D1 (Fig. 3D2) showed clusters of col-
loidal gold particles of different sizes corresponding to
IDE (black arrows, 6 nm) and Aβ (white arrows, 15 nm)
detected on the PM. The experimental evidences that Aβ
levels are significantly increased in DRM as compared to
DSM and the highly specificity of the immunogold
strongly suggest that DRMs may be one of the sub-cellular
compartments where IDE and Aβ interact.
IDE isolated from DRMs of rat brain is proteolitically 
active in vitro
To determine if DRM-associated IDE was proteolytically
active, we examined degradation of insulin (the most spe-
cific substrate for IDE) and Aβ (a relevant substrate for AD
Endogenous IDE is localized in DRMs of living cells Figure 2
Endogenous IDE is localized in DRMs of living cells. 
A- Living N2aWT cells (panel 1–3) and primary hippocampal 
neurons (panel 4–6) were stained to label DRMs (panel 1 and 
4) and IDE (panel 2 and 5). Merged images showed partial co-
localization (arrows) on the PM (panel 3 and 6). Scale bar, 5 
μm (panel 1–3) and 20 μm (panel 4–6).B- Immunogold elec-
tron microscopy on cryosections of N2aSW cells showed 
clusters of gold particles at the PM (panel 1). A higher magni-
fication of the section framed in panel 1 (panel 2) clearly indi-
cated co-localization of gold particles of different size 
corresponding to flotillin-1 (black arrows, 6 nm size) and IDE 
(white arrows, 15 nm size). Scale bar, 50 nm.
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Endogenous IDE co-localizes with flotillin-1 and Aβ on the  plasma membrane Figure 3
Endogenous IDE co-localizes with flotillin-1 and Aβ 
on the plasma membrane. A- Brain rat membranes were 
processed as described in Materials and Methods and frac-
tions analyzed by refractive index (h), distribution of total 
protein (m) and GPI-anchored alkaline phosphatase activity 
(r). DRMs, fraction 3–4; DSMs, fractions 8–9. Fraction 1, top 
of the gradient; fraction 9, bottom of the gradient.B- Repre-
sentative western blotting of the same amount of total pro-
tein from DRMs and DSMs isolated from cortical tissue of a 
FAD brain showed co-localization of IDE and flotilin-1 in 
DRMs. IF, intermediate fraction. C- Significant increased 
amount of Aβ 42 was detected in DRM compared to DSM by 
ELISA. Bars represent means ± S.E.M of 2 independent 
experiments. *p < 0.001. D- Immunogold electron micros-
copy on cryosections of N2aSW cells showed clusters of 
gold particles at the plasma membrane (panel 1). A higher 
magnification of the section framed in panel 1 (panel 2) 
clearly indicated co-localization of gold particles of different 
size corresponding to Aβ (white arrow, 15 nm) and IDE 
(black arrows, 6 nm). Scale bar, 50 nm.
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pathology) by an immunoprecipitation-based assay.
DRM and DSM fractions were isolated from rat brain cor-
tex, and endogenous IDE was immunoprecipitated using
1C1 and 3A2 monoclonal antibodies. The presence of IDE
in immunoprecipitates was confirmed by western blotting
using BC2 anti-IDE antibody (Fig. 4A). Immunoprecipi-
tates were then incubated with [125I]-insulin or [125I]-
Aβ40, and degradation analyzed by SDS-PAGE followed
by phosphorimaging. The results showed substantial deg-
radation of substrates when reactions were performed in
the absence of 1,10 phenanthroline/EDTA (Fig. 4B). Con-
versely, addition of inhibitor strongly blocked degrada-
tion of insulin and Aβ, indicating substrate specificity of
IDE in the reactions. The partial resistance of Aβ to degra-
dation was likely due to the biophysical state of radiola-
beled peptide and the reported resistance of aggregated Aβ
to IDE proteolysis. Semi-quantitative analysis of the deg-
radation assays indicated that insulin degradation (Fig.
4C, upper panel) in the absence of 1,10 phenantroline/
EDTA was 83.8 ± 0.6% and 88.2 ± 0.3% in DRM and
DSM, respectively, while a significant degradation impair-
ment was detected in both fractions after IDE inhibition
(11.3 ± 0.3% and 1.2 ± 0.6% in DRM and DSM, respec-
tively; n = 3; p < 0.001). In addition, f [125I]-Aβ degrada-
tion (Fig. 4C, lower panel) in the absence of 1,10
phenantroline/EDTA was 41.2 ± 0.9% and 37.3 ± 0.9% in
DRM and DSM, respectively and values were significantly
decreased after the addition of metalloproteases inhibi-
tors (2.0 ± 1.0% and 1.5 ± 0.9% in DRM and DSM, respec-
tively, n = 3, p < 0.001). Our results clearly indicate that
DRM and DSM -associated IDE are proteolitically active in
vitro.
Manipulation of membrane lipid composition disrupts 
IDE-DRM association and affects A  degradation in intact 
cells
Taking into account that des-localization of a given protein
within a DRM as a consequence of lipid manipulations
strongly suggests lipid raft association in vivo, we deter-
mined the effect of Chol, sphingolipids (SL) and phospha-
titylcholine (PC) removalupon the association of IDE with
DRMs. N2aWT cells were treated with MβCD under exper-
imental conditions reported to be "mild", without associ-
ated cytotoxicity [30]. Membrane fractions from control
and MβCD-treated cells showed similar amounts of Chol
determined by an analytical procedure (1.26 μg/mg vs. 1.46
μg/mg) and similar amounts of IDE and flotillin (Fig. 5A)
with a sharp reduction in insulin degradation from MβCD-
treated cells which was statistically significant as compared
to control cells (28.6 ± 8.5% vs. 66.9 ± 1.5%; n = 3; p <
0.05) (Fig. 5B). To find a biochemical explanation for these
results we determined the membrane lipid composition
from control and MβCD-treated cells by thin-liquid chro-
matography (TLC). Our data showed a decrement in the
percentage of PC and SL in membranes from MβCD-
DRM- and DSM-associated IDE pools are proteolytically  active in vitro Figure 4
DRM- and DSM-associated IDE pools are proteolyti-
cally active in vitro. A- Western blotting with BC2 anti-
IDE polyclonal antibody of immunoprecipated IDE from iso-
lated DRM and DSM fractions of rat brain using 1C1/3A2 
anti-IDE monoclonal antibodies. B- Representative phos-
phorimage scan showed degradation of [125I]-insulin and 
[125I]-Aβ after incubation with anti-IDE immunoprecipitates 
from DRM and DSM in the presence of a protease inhibitor 
cocktail (as defined in Antibodies and Chemicals) with or 
without metalloprotease inhibitors (EDTA/1,10 phenantro-
line). IgG, unrelated immunoglobulin used as a negative con-
trol for the immunoprecipitation. The intensity of the band in 
the presence of unrelated IgG and after incubation in degra-
dation buffer was referred as intact substrate (0% degrada-
tion). C- Bars represent the semi-quantitative analysis of the 
percentage of [125I]-insulin and [125I]-Aβ degradation by IDE 
from DRMs and DSMs in the presence and absence of 1,10-
Phe/EDTA (n = 3; *p < 0.001).
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treated as compared to control cells (30% and 2.39% vs.
44% and 4.25%). In addition, we showed lipid-dependent
changes in IDE- and flotillin-DRM association (Fig. 6A,
framed region). In this regard, DRMs (fraction 3 and 4)
from untreated cells (Fig. 6B upper panel, black bar) retain
12.6 ± 0.6% of total membrane-associated IDE and 45.2 ±
1.1% of total membrane-associated flotillin (Fig. 6B lower
panel, black bar) while no reactivity for IDE was detected in
DRMs of MβCD-treated cells (Fig. 6B upper panel, white
bar) and only a 32.5 ± 0.6% (n = 3; p < 0.05) of flotillin
reactivity was observed (Fig. 6B, lower panel, white bar).
Lipid manipulations induced a rise of IDE immunoreactiv-
ity in "intermediate fractions" (fractions 6–8) from 47.4 ±
2.3% to 66.2 ± 1.7%.
Re-localization of IDE and flotillin to DRM in a percent-
age similar to control cells was obtained when water-sol-
PM-IDE activity in vitro is impaired after manipulation of  membrane lipid composition Figure 5
PM-IDE activity in vitro is impaired after manipula-
tion of membrane lipid composition. A- Representative 
western blotting of IDE and flotillin-1 showed no differences 
in the protein levels in membranes isolated from control 
(CTL) and Mβ CD-treated cells.B- Representative Phos-
phorImage scan showed degradation of [125I]-insulin after 
incubation with membranes isolated from cells treated or 
not with Mβ CD in the presence of a protease inhibitor 
cocktail (as described in Antibodies and Chemicals) with or 
without metalloprotease inhibitors (1,10 phenantroline/
EDTA). Bars showed the semi-quantitative analysis of the 
percentage of [125I]-insulin degradation by endogenous IDE 
from control and MβCD-treated membranes (n = 3; *p < 
0.05).
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Association of endogenous IDE with DRMs is sensitive to  membrane-lipid composition Figure 6
Association of endogenous IDE with DRMs is sensi-
tive to membrane-lipid composition. A-Sucrose gradi-
ent fractions from N2aWT cells control (CTL), treated with 
MβCD alone (MβCD) or replenished with soluble Chol 
(MβCD + Chol) analysed by western blotting with anti-IDE 
and anti-flotillin-1 antibodies, respectively. Framed region, 
DRMs (fractions 3 and 4). B- Bars showed the percentage of 
total endogenous IDE and flotillin-1 in sucrose gradient frac-
tions 3 and 4 (DRMs) from CTL (filled bars), MβCD (open 
bars) and MβCD + Chol (dashed bars). IDE and flotillin-1 
were dramatically affected by membrane-lipid manipulation 
(n = 3; *p < 0.05 as compared to CTL values in each frac-
tion). Fraction 2: top of the gradient. Fraction 9: bottom of 
the gradient.
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uble Chol was added to MβCD-treated cells (Fig. 6B upper
and lower panels, dashed bar). Moreover, we immuno-
precipitated IDE from DRMs and DSMs of control and
MβCD-treated cells and incubated the immunoprecipi-
tates with exogenous [125I]-Aβ. As it is shown in Fig. 7A a
significant decrement of IDE activity was observed in
DRMs from MβCD-treated cells as compared to control
(6.55 ± 2.05% vs. 24.3 ± 1.1%; n = 2; p < 0.05) while no
significant differences were detected in DSMs fractions
from treated and control cells, respectively (57.5 ± 2.5%
vs. 59.5 ± 2.7%; n = 2; p > 0.05). To assess if IDE mis-loca-
tion from DRMs affects Aβ clearance, N2aWT intact cells
were treated or not with MβCD in the presence of protease
inhibitors as described above and exposed to nM concen-
trations of exogenous [125I]-Aβ. A significant reduction in
[125I]-Aβ degradation was observed in MβCD-treated cells
as compared to control (24.1 ± 2.0% vs. 36.9 ± 3.3%; n =
6; p < 0.05) (Fig. 7B). The addition of water soluble Chol
to MβCD-treated cells restored the degradation profile to
values similar to control cells (35.6 ± 3.1%, n = 6) indicat-
ing that DRMs-associated IDE is involved in the degrada-
tion of exogenous Aβ in living cells.
To determine the role of DRM-associated IDE on the
steady-state levels of endogenous Aβ, we incubated
N2aSW cultures in the presence or absence of MβCD as
described above and the supernatant collected after 12
and 24 hours, respectively, for extracellular Aβ40 quanti-
fication. The experiments were performed in the presence
of phosphoramidon, thiorphan and leupeptin to avoid
NEP, ECE or plasmin activity. As depicted in Fig. 7C the
extracellular levels of Aβ40 progressively accumulated
after lipid efflux from the plasma membrane reaching val-
ues of 1.13 ± 0.02 and 1.66 ± 0.03 pg/μg of cellular pro-
tein as compared to control cells (0.62 ± 0.005 and 0.69 ±
0.01 pg/μg of cellular protein) after 12 h and 24 hours,
respectively, (p < 0.05; n = 2). No significant change was
observed in the levels of APP C-terminal fragments (Fig.
7C, inset) ruling out the unlikely possibility of an
increased Aβ production during the incubation. Together
with the in vitro results, these evidences suggested that the
steady-state level of Aβ was significantly modified when
IDE activity was displaced from DRMs.
Brain cholesterol levels modulate IDE-DRM association in 
vivo
To determine the impact of brain Chol levels on IDE
localization in vivo, mice with a targeted deletion of one
seladin-1 (sel-1) allele (+/-) were used. Membranes from
sel-1 (+/-) mouse brains showed reduced levels of Chol as
compared to wild type sel-1 (+/+) mice (2.57 μg/mg vs.
5.55 μg/mg) and disorganized DRMs [31]. The flotation
profiles of IDE and flotillin from sel-1 (+/+) mouse brains
(Fig. 8A, upper panel) showed no significant differences
as compared to rat or human brain as described above. In
Effect of disorganized DRM on Aβ degradation mediated by  IDE Figure 7
Effect of disorganized DRM on Aβ degradation medi-
ated by IDE. A- Bars showed percentage of degraded [125I]-
Aβ by IDE immunoprecipitated from DRM and DSM frac-
tions from membranes treated or not with MβCD (n = 2; *p 
< 0.05). B- Bars showed the semi-quantitative analysis of the 
percentage of degraded extracellular [125I]-Aβ in the condi-
tioned media of control, MβCD treated and Chol replen-
ished N2aWT cells (n = 6; *p < 0.05). C- Upper panel, 
representative western blotting of C-terminal APP and tubu-
lin levels from N2aSW cellular homogenates showed no dif-
ferences between control (CTL) and MβCD-treated cells. 
Lower panel, bars represented Aβ 40 levels in the superna-
tants of CTL and MβCD-treated cells after 12 and 24 hours 
of incubation (n = 2; *p < 0.05).
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agreement with a DRM-specific shortage, reduction of
brain sel-1 levels resulted in the displacement of IDE and
flotillin (Fig. 8A, lower panel) from DRM. Thus, while in
sel-1 (+/+) mice 27.7 ± 1.36% of the total IDE and 41.2 ±
0.76% of total flotillin resides in fractions 3 and 4, respec-
tively, only 11.9 ± 0.4% and 34.8 ± 0.85% (n = 3; p <
0.05) of IDE and flotillin, respectively, was observed in
sel-1 (+/-) brains (Fig. 8B). Decreased Chol levels induced
a rise of IDE immunoreactivity in "intermediate fractions"
(fractions 5–7) of sel (+/-) as compared to sel (+/+) mice
brains (62.0 ± 1.3% vs. 28.3 ± 1.5%, respectively). As
expected, a drop in [125I]-insulin degradation by IDE in
sel-1 (+/-) was observed as compared to sel-1 (+/+) brains
(2.6 ± 1.7% vs. 21.9 ± 0.9%; n = 2; p <0.05) (Fig. 8C).
Discussion
Together our results of live immunofluorescence on
unpermeabilized cells, immunoelectron-microscopy and
gradient fractionation concurred to the demonstration
that IDE is, in addition to its other localizations, a DRM-
associated metallopeptidase. Noteworthy, the analysis of
IDE primary structure shows no evidence for membrane-
binding sequences, no post-translational modifications
are known and our metabolic labeling studies (not
shown) with [3H]-palmitate and [3H]-ethanolamine did
not support palmitoylation or GPI anchor (Morelli L,
unpublished observations). However, the existence of
DRM-associated proteins lacking these motifs has been
demonstrated. In these cases, inclusion into DRMs was
postulated to be mediated by mechanisms involving pro-
tein-protein interactions [32], direct association through
post-translational modifications [33] or changes in the
conformational state of the cytosolic protein [34]. IDE
may be anchored directly to DRMs by a yet uncharacter-
ized post-translational modification or indirectly through
a strong interaction with a protein residing in these struc-
tures. The specificity of our monoclonal antibodies
together with the degradation assays in intact cells indi-
cated that at least the IDE N-terminal domain including
the catalytic site had a fully functional extracellular loca-
tion. Taking into account the requirement of the C-termi-
nal domain for substrate binding [35] it is likely that the
entire IDE molecule is located on the cell surface. This
notion is in accordance with previous work showing the
cell surface biotinylation of IDE [26] and the more recent
demonstration that IDE may act as a cellular receptor for
Varicella Zoster virus [36].
Results from the pulse chase experiments are in accord-
ance with the existence of at least two pools of cellular
IDE. The cytosolic one with a longer half-life as previously
reported [37] and the membrane-IDE with faster turn-
over, in agreement with reports described for DRM resi-
dent proteins [38,39]. Significant differences between the
t1/2 of both pools of IDE are predictable and reasonable
taking into account that each pool may undergo different
degradative pathways.
Our finding that a pool of active IDE is associated with
DRMs is highly relevant to Aβ and insulin metabolism.
DRMs appear to be central to the process of Aβ aggrega-
tion in the course of the disease, as suggested by AD ani-
mal models [29]. The co-fractionation of IDE activity and
Aβ in DRMs in addition to the evidence that Aβ degrada-
tion is impaired by DRMs disruption raises the possibility
that a substantial part of Aβ proteolytic removal may take
place at DRMs. This hypothesis is further supported by the
Impact of brain cholesterol levels on endogenous IDE locali- zation and activity Figure 8
Impact of brain cholesterol levels on endogenous IDE 
localization and activity. A-Sucrose gradient fractions 
from sel-1 (+/+) and (+/-) mouse brains analyzed by western 
blotting with anti-IDE and anti-flotillin, respectively. Framed 
region, DRMs (fractions 3 and 4). Fraction 2: top of the gradi-
ent. Fraction 9: bottom of the gradient. B- Upper panel, bars 
showed the semi-quantitative analysis of the percentage of 
total endogenous IDE and flotillin-1 immunoreactivity in 
sucrose gradient fractions 3 and 4 (DRMs) from control 
(open bars) and partially knocked-out mice (filled bars). IDE 
and flotillin-1 present in DRM fraction were significant 
affected in sel-1 (+/-) mice brain compared to (+/+) mice (n = 
3; *p < 0.05). C- Bars showed the semi-quantitative analysis 
of the percentage of [125I]-insulin degradation by endogenous 
DRMs-bound IDE from sel (+/+) and sel (+/-) brain mem-
branes in the presence of a protease inhibitor cocktail as 
described in Antibodies and Chemicals (n = 2; *p < 0.05).
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fact that two other proteases involved in Aβ degradation -
NEP and plasmin- are also present in DRM [22,29]. Here
we show that MβCD treatment resulted in a decrement of
the PC and SL levels associated with a significant displace-
ment of IDE from DRMs with a reduction on Aβ clearance.
PC is the main cell glycerophospholipid, and it is the
main lipid component of lipid membrane domains from
cerebelar neurons [40]. Thus the reduction in the content
of PC can be considered a good indication of a general
reduction of the surface area occupied by the lipid
domain. Our experimental evidences propose that lipid
content in DRMs may modulate not only Aβ generation
[41,42] but also its degradation. In this regard, it was pre-
viously reported that Chol depletion by combination of
lovastatin (which decreases de novo synthesis of Chol)
and MβCD (which promotes lipid efflux from the plasma
membrane), inhibits Aβ secretion in hippocampal neu-
rons, probably due to changes in the intracellular trans-
port of APP, enhanced APP α-cleavage and decreased APP
β-cleavage, respectively [41,43,44]. Moreover, the Aβ-low-
ering effect of Chol manipulations was not observed in
COS cells stably transfected with human APP695 [41]. In
addition, it was reported that Chol depletion of mem-
branes from CHO cell lines stably co-expressing wild type
human APP and presenilins, did not affect the γ-secretase
activity present in DRMs [45]. In this context, our results
suggest that the sole efflux of Chol, PC and SL from the
plasma membrane, without the effect of inhibiting Chol
synthesis, probably does not affect APP processing and
the consequent Aβ generation but instead may negatively
impact on Aβ clearance mediated by DRMs-associated Aβ
proteases. The evidences that Aβ clearance is impaired
when IDE is shifted from DRMs, even if DSM-associated
IDE is proteolytically active in vitro, suggest an important
role of membrane lipid composition in the activity of
enzymes associated with membranes in living cells. It is
possible that membrane-associated IDE conformational
requirement and its interaction with other proteins for
substrate degradation are only optimal in the context of
organized DRMs. This may explain why, in our experi-
ments in vitro using membranes isolated from MβCD-
treated cells or from mouse brain of sel-1 (+/-) mice, a
shift of IDE from DRMs (82% in MβCD-treated cells and
55.5% in sel-1 (+/-) mouse brain) induced a substantial
decrement on IDE proteolytic activity (73% and 88% in
MβCD-treated cells and sel-1 (+/-) mouse brain, respec-
tively).
Alternatively, DRMs but not DSMs, may act as platforms
where Aβ accumulates, due to its hydrophobic properties,
reaching local concentration close to its Km for IDE. Our
experiments with intact cells where the extracellular con-
centration of Aβ was approximately 0.2 nM (far below the
known Km of IDE for Aβ~1–2 μM) showed that the deg-
radation was inefficient in intact cells pre-treated with
MβCD. It was previously reported that when the loss of
lipids is relative limited, as the case of a "mild" MβCD
treatment, the membrane lipids change their membrane
organization, reducing the total surface area of membrane
lipid domains. This can be achieved by reducing the total
number of domains or their sizes [46]. The accumulation
of endogenous Aβ after lipid manipulations further sup-
ports this possibility. Although a broad protease inhibi-
tion was used (including NEP, ECE and plasmin), we
cannot rule out a contributory effect of matrix metallo
peptidases [47]. Alternatively, reduced binding and
uptake of Aβ due to lipid manipulation of the PM needs
to be further examined as a possible contributory mecha-
nism of Aβ accumulation.
Taking into account that it was previously demonstrated
that only moderate levels of desmosterol accumulate in
brains of sel-1 (+/-) mice and that the exogenous addition
of desmosterol to neuroblastoma cells has no effect in the
flotation profile of DRMs enriched proteins [31] we
assume that the differences observed in IDE proteolytic
activity between sel-1 (+/+) and sel-1 (+/-) brains were
due to lower Chol in DRMs rather than to an inhibitory
effect of desmosterol. These results are in agreement with
the evidence that in sel-1 (+/-) mice, steady-state levels of
brain Aβ are significantly elevated, and human Aβ accu-
mulates in sel-1 (+/-) mice bred to transgenic mice overex-
pressing APP harboring the Swedish mutation [31].
Our data of the relevance of DRMs integrity in IDE medi-
ated proteolysis are in accordance with the behavior of the
insulin receptor (IR) which, after Chol depletion, is able
to interact with insulin but unable to propagate the insu-
lin signaling cascade due to its mis-location from the
DRMs [48]. In this scenario, our results lead us to suggest
that structural integrity of DRMs may be required to
tightly retain IR and IDE for at least 2 functions: 1- further
downstream insulin signaling and 2- insulin proteolysis
once in the endocytic vesicle which contains receptor, lig-
and and enzyme.
The relationship among DRMs integrity, lipid content, sel-
1 expression and AD pathology has been extensively
reported [22,31,49-51] and alterations of DRM composi-
tion in the course of AD have been described [52]. More-
over, abnormal DRM lipid composition has been
suggested as a molecular mechanism involved in insulin
resistance, thought to be the primary defect in the patho-
physiology of type 2 diabetes [53]. In this regard, it is
noteworthy that disturbances in insulin metabolism,
especially insulin resistance, may play a role in pathogenic
processes that promote the development of sporadic AD.
Individuals suffering from AD had been shown to have
lower cerebrospinal fluid and higher plasma insulin con-
centration [54]. Since insulin has been shown to affect AβMolecular Neurodegeneration 2008, 3:22 http://www.molecularneurodegeneration.com/content/3/1/22
Page 12 of 13
(page number not for citation purposes)
and IDE levels and tau hyperphosphorylation in the
brain, this issue has recently emerged as a novel field of
sporadic AD ethiopathogenesis and therapy research [55].
Conclusion
It has been suggested that protease-mediated Aβ clearance
becomes inefficient with aging [56] and the impact of a
reduction in DRM-associated IDE may be particularly sig-
nificant. Minor changes in Aβ levels may dramatically
affect its oligomerization rate with the consequent escape
of Aβ from the physiologic pathway of proteolytic
removal. The concept that mis-location of IDE and other
Aβ degrading proteases away from DRMs may impair the
physiological turn-over of Aβ in vivo deserves further
investigation in light of therapeutic strategies based on
enhancing Aβ proteolysis in which DRM protease-target-
ing may need to be taken into account.
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